Jonathan Colasanti, MD, MSPH, shares how the introduction of a Rapid Entry Program in Atlanta proved successful at improving access to HIV care and viral suppression rates.
Dr. Richard Vickers, discusses C. difficile rates in the United Kingdom.
Debra Goff, PharmD, FCCP, explains how technology can be incorporated into antimicrobial stewardship programs.
Barley Chironda, RPN, CIC, discusses different high-touch surfaces in hospital rooms that are known to harbor pathogenic bacteria.
Marin H. Kollef, MD, discusses treatment options for Pseudomonas aeruginosa.
Glenn Tillotson, PhD, FIDSA, provides insight into the growing problem and cost of antimicrobial resistance.
Leonard Sigal, MD, explains his approach for treating Lyme disease patients with persistent symptoms.
Dr. Richard Vickers, discusses what the next steps are for Summit Therapeutic’s ridinilazole.
Marin H. Kollef, MD, discusses what to consider when calling for cultures.
Debra Goff, PharmD, FCCP, explains the role that antimicrobial stewardship programs have in the fight against multidrug-resistant infections.
Edmond Hooker, MD, DrPH, stresses that the FDA and the CDC need to intervene to ensure that hospital mattresses get cleaned appropriately.
Barley Chironda, RPN, CIC, stresses that understanding what motivates health care workers’ actions is crucial for reducing C. diff rates in hospitals.
Glenn Tillotson, PhD, FIDSA, explains how costs associated with Clostridium difficile compare with other problematic health care-associated infections.
Marin H. Kollef, MD, explains why Pseudomonas infections are getting harder to treat.
Richard Haupt, MD, MPH, explains why it’s harder to cover adults rather than children when it comes to vaccination.
Edmond Hooker, MD, DrPH, discusses a study that assessed the use of mattress covers in hospitals to cut down on CDI rates.
Barley Chironda, RPN, CIC, discusses why some health care workers are not practicing good hand hygiene and ways to motivate them to do so.
Dr. Richard Vickers, explains how ridinilazole affected the gut microbiome in participants of a phase 2 study.
Leonard Sigal, MD, explains his approach for treating patients who may have “Lyme anxiety.”
Marin H. Kollef, MD, discusses Pseudomonas aeruginosa infections within the intensive care unit.
Glenn Tillotson, PhD, FIDSA, discusses the costs of drug development.
Edmond Hooker, MD, DrPH, discusses how contaminated hospital mattresses act as a vector for spreading drug-resistant infections.
Dr. Richard Vickers, discusses how ridinilazole showed superior efficacy for the treatment of C. diff when compared with vancomycin in a phase 2 study.
Richard Haupt, MD, MPH, discusses what is needed to ensure that a future C. diff vaccine is adequately stocked and delivered to wherever individuals show up for vaccination.
Robert Bransfield, MD, DLFAPA, explains how open minds are needed to understand how infections can impact cognitive function and conduct.
Marin H. Kollef, MD, discusses the mortality and health care costs associated with Pseudomonas infections.
Barley Chironda, RPN, CIC, discusses current guidance for disinfection practices against C. diff.
Leonard Sigal, MD, explains the term “Lyme anxiety” and its association with a chronic Lyme disease diagnosis.
Edmond Hooker, MD, DrPH, discusses the cost benefit of investing in launderable hospital mattress covers to prevent CDIs.
Dr. Richard Vickers, explains how ridinilazole is unique in its spectrum of activity compared with other antibiotics that target C. diff and have been approved or are in development.
